Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.

CONCLUSION: 177Lu-PSMA SPECT scan can help detecting metastatic lesions in more than one third of patients with biochemical recurrence and negative conventional investigations, when 68Ga- PSMA PET is not available. PMID: 32281092 [PubMed - as supplied by publisher]
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research

Related Links:

Conclusion: The high accumulation of activity in the tumor and fast clearance from background organs was a common favorable characteristic of PSMA radioligands modified with ibuprofen as albumin-binding entity. 177Lu-Ibu-DAB-PSMA emerged as the most promising candidate; hence, more detailed preclinical investigations with this radioligand are warranted in view of a clinical translation.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: This work demonstrates a means for efficient dose estimation in 177Lu-PSMA-617 therapy. By providing methods to simplify and potentially automate radiation dosimetry, we hope to accelerate the understanding of radiobiology and development of dose–response models in this unique therapeutic context.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
AbstractMetabolic bone volume (MBV), standardized uptake value (SUV), and total bone uptake (TBU) are new imaging biomarkers for quantitative bone single-photon emission computed tomography/computed tomography. The purpose of this study was to validate the quantitative accuracy and utility of MBV, SUVmean, and TBU for the assessment of bone metastases in prostate cancer. We used a bone-specific phantom with four hot spheres (φ = 13, 17, 22, 28 mm) filled with different Tc-99 m activities to simulate uptake ratios of 3 and 7, corresponding to normal and metastatic values. We calculated the error ...
Source: Radiological Physics and Technology - Category: Physics Source Type: research
1273Background: Ra-223-dichloride treatment of castration-resistant prostatic cancer has an alpha radiation-induced radiotherapeutic effect on bone metastases and prolongs the prognosis, but the mechanism by which the prognosis is prolonged is not well understood.Objectives: The purpose of this study was to observe the changes in bone accumulation using bone scintigraphy during Ra-223-dichloride therapy with a precise single-photon emission computed tomography (CT)/CT (SPECT/CT) device.Subjects and Methods: The subjects were 28 patients with Ra-223-dichloride therapy for castration-resistant prostate cancer bone metastases...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: GU - Radioligand Therapy (Poster Session) Source Type: research
Background 99mTc-MIP-1404 is a SPECT-suitable prostate-specific membrane antigen (PSMA) ligand for detection of prostate cancer. In patients with metastatic prostate cancer, there are no data as yet on interobserver and intraobserver variability when assessing PSMA-positive lesions for longitudinal changes of tracer uptake. Methods 99mTc-MIP-1404 SPECT/CT scans of 22 patients with metastatic prostate cancer were analyzed, and each subject was imaged at 2 separate points in time, before and after treatment. Mean interval between scans was 10 months. Three independent observers visually assessed a total of 96 PSMA-posit...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
AbstractObjectiveQualitative interpretation in bone scan is often complicated by the presence of degenerative joint disease (DJD), especially in the elderly patient. The aim of this study is to compare objectively99mTc-MDP tracer uptake between DJD and osseous metastases of the spine using semi-quantitative assessment with SPECT SUV.MethodsBone scan with SPECT/CT using99mTc-MDP was performed in 34 patients diagnosed with prostate carcinoma. SPECT/CT was performed based on our institutional standard guidelines. SUVmax based on body weight in 238 normal vertebrae visualized on SPECT/CT was quantified as baseline. A total of ...
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
Ulrika Rosenström Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) could improve the diagnostic accuracy in prostate cancer (PCa). The aim of this study was to develop a PSMA/GRPR-targeting bispecific heterodimer for SPECT and positron emission tomography (PET) diagnostic imaging of PCa. The heterodimer NOTA-DUPA-RM26 was produced by manual solid-phase peptide synthesis. NOTA-DUPA-RM26 was labeled with 111In and 68Ga, with yields >98%, and demonstrated a high stability and binding specificity to PSMA and GRPR. IC50 values for natIn-NOTA-DU...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 1 August 2019Source: Inorganica Chimica ActaAuthor(s): F. Cortezon-Tamarit, A. Baryzewska, M. Lledos, S.I. PascuAbstractIn recent years, the use of metallic isotopes for nuclear imaging techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) has become an area of much interest. In particular, PET is a molecular imaging modality that relies on the detection of two antiparallel, co-linear gamma rays (511 keV) emitted when a positron undergoes annihilation with an electron. PET isotopes of interest in medical practice are numerous and thei...
Source: Inorganica Chimica Acta - Category: Chemistry Source Type: research
ConclusionsThe results of this study demonstrate the successful preparation and preclinical testing of152Tb-PSMA-617 and its first application in a patient with mCRPC. This work could pave the way towards clinical application of other Tb radionuclides in the near future, most importantly161Tb, which has promising decay characteristics for an effective treatment of mCRPC patients.
Source: EJNMMI Research - Category: Radiology Source Type: research
539Objectives: Both, the kidneys and the bone marrow, are considered as organs at risk in Lu-177-PSMA therapy of metastasized castration-resistant prostate cancer (mCRPC). mCRPC patients often present with a high tumor load, which may affect the risk of kidney or bone marrow toxicities via tumor sink effects. The aim of this work was to assess kidney and bone marrow absorbed doses in correlation to the patient-specific tumor load. Methods: The study is based on the first cycle of 14 patients, treated with 3.7 or 6 GBq Lu-177-PSMA-DKFZ-617. Each patient received a pre-therapeutic Ga-68-HBED-CC-PSMA PET/CT, abdominal SPECT a...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Therapy II Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Nuclear Medicine | PET Scan | Prostate Cancer | SPECT | Study | Urology & Nephrology